Spoiled for Choice: P2Y 12 Receptor Inhibition in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Authors :: Sibbing D
Massberg S
Rizas KD
Source :: JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2024 Jun 10; Vol. 17 (11), pp. 1371-1373.
Publication Year :: 2024
Abstract: Competing Interests: Funding Support and Author Disclosures Dr Sibbing has received speaker fees and fees for advisory board activities from Bayer, Daiichi-Sankyo, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Subjects :: Humans
Treatment Outcome
Risk Factors
Platelet Aggregation Inhibitors therapeutic use
Platelet Aggregation Inhibitors adverse effects
Clinical Decision-Making
Coronary Artery Disease therapy
Coronary Artery Disease diagnostic imaging
Risk Assessment
Hemorrhage chemically induced
Atrial Fibrillation physiopathology
Atrial Fibrillation drug therapy
Atrial Fibrillation diagnosis
Percutaneous Coronary Intervention adverse effects
Purinergic P2Y Receptor Antagonists therapeutic use
Purinergic P2Y Receptor Antagonists adverse effects

Full Text Access

Tools